The Patient-Centered Outcomes Research Institute (PCORI) will be releasing the “Comparative Effectiveness of Novel Pharmacologic and Evidence-based Nonpharmacologic Treatments for Migraine Prevention” Targeted PCORI Funding Announcement (PFA) on September 7, 2021.
This Targeted PFA seeks to fund rigorous large-scale pragmatic trials that compare newly available pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine. PCORI is particularly interested in studies that compare emerging pharmacological options such as calcitonin gene-related peptide (CGRP) antagonists to standard prophylactic therapy or to each other. PCORI is also interested in studies that examine the comparative effectiveness of evidence-based nonpharmacological options for migraine prevention. As appropriate, studies may include nonpharmacological interventions as stand-alone therapy or as an adjunct to pharmacological options.
Applicants should consider a broad range of outcomes that are important to patients. Pharmacologic studies should be adequately powered to assess changes in the frequency of headache or migraine days, while considering evidence gaps regarding long-term effectiveness. Other important outcomes of interest include quality of life, headache-related disability, patient burden (i.e., time away from work or usual activities), functional impact, tolerability, adverse events, and use of abortive treatment.
PCORI invites you to review the full preannouncement on their website for more information about this Targeted PFA and register for the town hall on September 15, 2021, at 1:30 PM ET.
